Molecular mechanism of Doxorubicin resistance in multiple myeloma cell line.
10.7534/j.issn.1009-2137.2014.05.029
- Author:
Yan-Yan LU
1
;
Cui-Rong XIAO
1
;
Hua-Ying CHEN
1
;
Xiao HUANG
1
;
Jia-Sheng HU
1
;
Quan-Yi LU
2
Author Information
1. Department of Hematology, Xiamen University Zhongshan Hospital, Xiamen 361004,Fujian Province, China.
2. Department of Hematology, Xiamen University Zhongshan Hospital, Xiamen 361004,Fujian Province, China. E-mail: quanyilu@ hotmail.com.
- Publication Type:Journal Article
- MeSH:
Antibiotics, Antineoplastic;
pharmacology;
Cell Line, Tumor;
Doxorubicin;
pharmacology;
Drug Resistance, Neoplasm;
Humans;
Interleukin-6;
Multiple Myeloma;
metabolism;
pathology;
Signal Transduction
- From:
Journal of Experimental Hematology
2014;22(5):1336-1340
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the molecular mechanism of doxorubicin resistance in multiple myeloma cell line and certify the effect of Notch signal over-expression on drug resistance of myeloma cells. The doxorubicin RPMI 8226 cell line (RPMI8226/DOX) was established by culturing 8226 cells with continuous low concentration and intermittent gradually-increasing-concentration of doxorubicin in vitro, the mRNA expression of Notch2,Jagged1, Jagged2, HES1 were measured by RT-PCR and the P-170 protein expression was detected by Western blot in RPMI 8226 cell line; the changes of IL-6 and VEGF were tested by ELISA. The results showed that the Notch mRNA expression (Notch2, Jagged1, Jagged2 increased gradually along with the increase of chemotherapeutic drug resistance, but the expression of HESI mRNA gradually decreased along with the increase of drug resistance. The expression level of P-170 protein was upregulated gradually along with the increase of drug resistance. The level of VEGF and IL-6 in culture supernatants of RPMI8226/DOX was higher than that in RPMI 8226. It is concluded that the establishment of RPMI 8226/DOX cell line is a useful model to analyze the mechanism of chemotherapeutic drug resistance in multiple myeloma, Notch activation is closely correlated with the drug resistance of multiple myeloma and Notch signaling may to be used as a new target for multiple myeloma treatment.
